Literature DB >> 26383016

Elucidation of The Behavioral Program and Neuronal Network Encoded by Dorsal Raphe Serotonergic Neurons.

Daniel J Urban1, Hu Zhu1, Catherine A Marcinkiewcz2, Michael Michaelides3, Hidehiro Oshibuchi4, Darren Rhea4, Dipendra K Aryal5, Martilias S Farrell1, Emily Lowery-Gionta2, Reid H J Olsen1, William C Wetsel5, Thomas L Kash2, Yasmin L Hurd3, Laurence H Tecott4, Bryan L Roth1.   

Abstract

Elucidating how the brain's serotonergic network mediates diverse behavioral actions over both relatively short (minutes-hours) and long period of time (days-weeks) remains a major challenge for neuroscience. Our relative ignorance is largely due to the lack of technologies with robustness, reversibility, and spatio-temporal control. Recently, we have demonstrated that our chemogenetic approach (eg, Designer Receptors Exclusively Activated by Designer Drugs (DREADDs)) provides a reliable and robust tool for controlling genetically defined neural populations. Here we show how short- and long-term activation of dorsal raphe nucleus (DRN) serotonergic neurons induces robust behavioral responses. We found that both short- and long-term activation of DRN serotonergic neurons induce antidepressant-like behavioral responses. However, only short-term activation induces anxiogenic-like behaviors. In parallel, these behavioral phenotypes were associated with a metabolic map of whole brain network activity via a recently developed non-invasive imaging technology DREAMM (DREADD Associated Metabolic Mapping). Our findings reveal a previously unappreciated brain network elicited by selective activation of DRN serotonin neurons and illuminate potential therapeutic and adverse effects of drugs targeting DRN neurons.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26383016      PMCID: PMC4793125          DOI: 10.1038/npp.2015.293

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  44 in total

Review 1.  Control of dorsal raphé 5-HT function by multiple 5-HT(1) autoreceptors: parallel purposes or pointless plurality?

Authors:  J A Stamford; C Davidson; D P McLaughlin; S E Hopwood
Journal:  Trends Neurosci       Date:  2000-10       Impact factor: 13.837

Review 2.  Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus.

Authors:  Christopher A Lowry; Matthew W Hale; Andrew K Evans; Jasper Heerkens; Daniel R Staub; Paul J Gasser; Anantha Shekhar
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 3.  Animal models of depression: an overview.

Authors:  P Willner
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

4.  Metabolic mapping of the effects of the antidepressant fluoxetine on the brains of congenitally helpless rats.

Authors:  Jason Shumake; Rene A Colorado; Douglas W Barrett; F Gonzalez-Lima
Journal:  Brain Res       Date:  2010-05-12       Impact factor: 3.252

5.  Remission of major depression under deep brain stimulation of the lateral habenula in a therapy-refractory patient.

Authors:  Alexander Sartorius; Karl L Kiening; Peter Kirsch; Carl C von Gall; Uwe Haberkorn; Andreas W Unterberg; Fritz A Henn; Andreas Meyer-Lindenberg
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

6.  Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.

Authors:  K Kroenke; S L West; R Swindle; A Gilsenan; G J Eckert; R Dolor; P Stang; X H Zhou; R Hays; M Weinberger
Journal:  JAMA       Date:  2001-12-19       Impact factor: 56.272

7.  Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression.

Authors:  S H Kennedy; K R Evans; S Krüger; H S Mayberg; J H Meyer; S McCann; A I Arifuzzman; S Houle; F J Vaccarino
Journal:  Am J Psychiatry       Date:  2001-06       Impact factor: 18.112

8.  Limbic-frontal circuitry in major depression: a path modeling metanalysis.

Authors:  D A Seminowicz; H S Mayberg; A R McIntosh; K Goldapple; S Kennedy; Z Segal; S Rafi-Tari
Journal:  Neuroimage       Date:  2004-05       Impact factor: 6.556

9.  Duration of antidepressant drug treatment. What is an adequate trial?

Authors:  F M Quitkin; J G Rabkin; D Ross; P J McGrath
Journal:  Arch Gen Psychiatry       Date:  1984-03

10.  Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants.

Authors:  Luca Santarelli; Michael Saxe; Cornelius Gross; Alexandre Surget; Fortunato Battaglia; Stephanie Dulawa; Noelia Weisstaub; James Lee; Ronald Duman; Ottavio Arancio; Catherine Belzung; René Hen
Journal:  Science       Date:  2003-08-08       Impact factor: 47.728

View more
  51 in total

Review 1.  Neural circuitry and mechanisms of waiting impulsivity: relevance to addiction.

Authors:  Jeffrey W Dalley; Karen D Ersche
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-18       Impact factor: 6.237

Review 2.  DREADDS: Use and application in behavioral neuroscience.

Authors:  Kyle S Smith; David J Bucci; Bryan W Luikart; Stephen V Mahler
Journal:  Behav Neurosci       Date:  2016-02-25       Impact factor: 1.912

Review 3.  Wiring the depressed brain: optogenetic and chemogenetic circuit interrogation in animal models of depression.

Authors:  Jessie Muir; Joëlle Lopez; Rosemary C Bagot
Journal:  Neuropsychopharmacology       Date:  2018-12-05       Impact factor: 7.853

Review 4.  Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs.

Authors:  C Joseph Burnett; Michael J Krashes
Journal:  J Neurosci       Date:  2016-09-07       Impact factor: 6.167

Review 5.  Optogenetic approaches for dissecting neuromodulation and GPCR signaling in neural circuits.

Authors:  Skylar M Spangler; Michael R Bruchas
Journal:  Curr Opin Pharmacol       Date:  2016-11-19       Impact factor: 5.547

Review 6.  The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats.

Authors:  Erin J Campbell; Nathan J Marchant
Journal:  Br J Pharmacol       Date:  2018-02-26       Impact factor: 8.739

7.  Selective activation of serotoninergic dorsal raphe neurons facilitates sleep through anxiolysis.

Authors:  Anne Venner; Rebecca Y Broadhurst; Lauren T Sohn; William D Todd; Patrick M Fuller
Journal:  Sleep       Date:  2020-02-13       Impact factor: 5.849

Review 8.  Combining designer receptors exclusively activated by designer drugs and neuroimaging in experimental models: A powerful approach towards neurotheranostic applications.

Authors:  Lore M Peeters; Stephan Missault; Aneta J Keliris; Georgios A Keliris
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

9.  Oral application of clozapine-N-oxide using the micropipette-guided drug administration (MDA) method in mouse DREADD systems.

Authors:  Sina M Schalbetter; Flavia S Mueller; Joseph Scarborough; Juliet Richetto; Ulrike Weber-Stadlbauer; Urs Meyer; Tina Notter
Journal:  Lab Anim (NY)       Date:  2021-02-22       Impact factor: 12.625

10.  Anatomically Defined and Functionally Distinct Dorsal Raphe Serotonin Sub-systems.

Authors:  Jing Ren; Drew Friedmann; Jing Xiong; Cindy D Liu; Brielle R Ferguson; Tanya Weerakkody; Katherine E DeLoach; Chen Ran; Albert Pun; Yanwen Sun; Brandon Weissbourd; Rachael L Neve; John Huguenard; Mark A Horowitz; Liqun Luo
Journal:  Cell       Date:  2018-08-23       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.